01—Abstract
Summary
Summary of the 10-K filed February 27, 2025. Cited figures are marked; the original filing is the authoritative source.
BeiGene Ltd. (ONC) demonstrated strong revenue growth in 2024, reaching $3.8 billiona, a significant increase from the prior year, driven primarily by the robust performance of its flagship oncology drug, BRUKINSA®.
The company also made strides in reducing its operating loss, achieving non-GAAP operating income for the first time and generating positive cash flows from operations in the latter half of 2024. This financial improvement is underpinned by BRUKINSA's market leadership in Chronic Lymphocytic Leukemia (CLL) in the U.S. and its expanding global reach. The company's strategic focus on a differentiated, wholly-owned hematology franchise with BRUKINSA, sonrotoclax, and its BTK-CDAC asset positions it well for sustained leadership in the $12 billionb global CLL market.
Beyond hematology, BeiGene is actively developing a deep pipeline in solid tumors, advancing 13 new molecular entities (NMEs) into the clinic in 2024, targeting prevalent cancers like breast, lung, and gastrointestinal cancers. The company's integrated business model, emphasizing internal clinical development capabilities and manufacturing, continues to be a key competitive advantage, enabling faster and more cost-effective development. BeiGene is well-positioned for continued growth and value creation for shareholders.
02—Key points
Key Highlights
- Achieved $3.8 billion in global revenue for 2024, a 55% increase year-over-year.
- BRUKINSA® sales reached $2.6 billion in 2024, demonstrating 105% year-over-year growth.
- Reduced GAAP operating loss and achieved positive non-GAAP operating income for the full year 2024.
- Generated positive cash flows from operations for the first time in Q3 and Q4 2024.
- Advanced 13 differentiated new molecular entities (NMEs) into the clinic in 2024.
- Continued to build a deep and innovative solid tumor pipeline with multiple programs advancing.
- Entered into a global licensing agreement for SYH2039, a MAT2A inhibitor for solid tumors.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2024, BeOne Medicines Ltd. lost $0.17.
- Revenue$3.81B100.0%
- Cost of revenue−$594.1M15.6%
- Gross profit$3.22B84.4%
- Operating costs−$3.78B99.3%
- Operating income−$568.2M14.9%
- Interest, other & tax−$76.6M2.0%
- Net income−$644.8M16.9%
04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 27, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $3.81B$2.46B | +55.0% |
| Gross Profit | $3.22B$2.08B | +54.7% |
| R&D Expenses | $1.95B$1.78B | +9.8% |
| SG&A Expenses | $1.83B$1.51B | +21.4% |
| Operating Expenses | $3.78B$3.29B | +15.1% |
| Operating Income | -$568.20M-$1.21B | +53.0% |
| Interest Expense | $46.89M$20.80M | +125.5% |
| Net Income | -$644.79M-$881.71M | +26.9% |
| EPS (Basic) | $-0.47$-0.65 | +27.7% |
| EPS (Diluted) | $-0.47$-0.65 | +27.7% |
| Shares Outstanding (Basic) | 1.37B1.36B | +0.9% |
| Shares Outstanding (Diluted) | 1.37B1.36B | +0.9% |
05—Questions
Frequently Asked Questions
What were the key drivers of BeiGene's revenue growth in 2024?
BeiGene's revenue growth in 2024 was primarily driven by the strong performance of BRUKINSA®, with global sales reaching $2.6 billion, a 105% increase year-over-year. The company also saw positive impacts from its in-licensed products from Amgen and its anti-PD-1 antibody, tislelizumab.
How is BeiGene positioned in the CLL market?
BeiGene is positioned as a leader in the CLL market with BRUKINSA®, which has become the leader in new patient starts in the U.S. for both frontline and relapsed/refractory CLL. The company's strategy to solidify its hematology franchise includes BRUKINSA as a cornerstone asset, complemented by its late-stage assets sonrotoclax (BCL2 inhibitor) and its BTK-CDAC, aiming to provide comprehensive solutions for CLL patients throughout their treatment journey.
What is BeiGene's strategy for its solid tumor pipeline?
BeiGene is focused on building depth in the most prevalent cancers, including breast/gynecologic, lung, and gastrointestinal cancers. In 2024, the company advanced 13 differentiated new molecular entities (NMEs) into the clinic, many with first-in-class or best-in-class potential, leveraging platforms such as antibody-drug conjugates (ADCs) and protein degraders.
What are the key financial milestones BeiGene anticipates in 2025?
BeiGene anticipates achieving positive GAAP operating income and operating cash flow in 2025. The company also plans to change its name to 'BeOne Medicines Ltd.' and transition to the NASDAQ ticker 'ONC'.
06—Continue